Blood-CNS barrier impairment in ALS patients versus an animal model

Frontiers in Cellular Neuroscience

Volumn 8, Issue FEB, 2014, Pages

  Garbuzova Davis, Svitlana ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Amyotrophic lateral sclerosis; Animal models; blood CNS barrier; Microvascular pathology; Patients

Indexed keywords

CD146 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN ZO1; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CAPILLARY LEAK SYNDROME; CELL ADHESION; CELL MIGRATION; DOWN REGULATION; HUMAN; PERICYTE; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 84893257209     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00021     Document Type: Review

References (108)

1. Abbott, N. J., and Romero, I. A. (1996). Transporting therapeutics across the blood-brain barrier. Mol. Med. Today 2, 106-113. doi: 10.1016/1357-4310(96)88720-X
2. Adams, C. W. (1988). Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 51, 260-265. doi: 10.1136/jnnp.51.2.260
3. Aggarwal, S., and Cudkowicz, M. (2008). ALS drug development: reflections from the past and a way forward. Neurother. J. Am. Soc. Exp. Neurother. 5, 516-527. doi: 10.1016/j.nurt.2008.08.002
4. Alexianu, M. E., Kozovska, M., and Appel, S. H. (2001). Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282-1289. doi: 10.1212/WNL.57.7.1282
5. Andjus, P. R., Bataveljić, D., Vanhoutte, G., Mitrecic, D., Pizzolante, F., Djogo, N., et al. (2009). In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer's-like disease: MRI approach. Anat. Rec. (Hoboken.) 292, 1882-1892. doi: 10.1002/ar.20995
6. Annunziata, P., and Volpi, N. (1985). High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 72, 61-64. doi: 10.1111/j.1600-0404.1985.tb01548.x
7. Appel, S. H., Zhao, W., Beers, D. R., and Henkel, J. S. (2011). The microglial-motoneuron dialogue in ALS. Acta Myol. 30, 4-8.
8. Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., et al. (2010). Pericytes regulate the blood-brain barrier. Nature 468, 557-561. doi: 10.1038/nature09522
9. Balabanov, R., and Dore-Duffy, P. (1998). Role of the CNS microvascular pericyte in the blood-brain barrier. J. Neurosci. Res. 53, 637-644. doi: 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6
10. Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13. doi: 10.1016/j.nbd.2003.12.016
11. Bartanusz, V., Jezova, D., Alajajian, B., and Digicaylioglu, M. (2011). The blood-spinal cord barrier: morphology and clinical implications. Ann. Neurol. 70, 194-206. doi: 10.1002/ana.22421
12. Bataveljić, D., Nikolić, L., Milosević, M., Todorović, N., and Andjus, P. R. (2012). Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1(G93A) rat model. Glia 60, 1991-2003. doi: 10.1002/glia.22414
13. Begley, D. J. (2004). ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10, 1295-1312. doi: 10.2174/1381612043384844
14. Begley, D. J., and Brightman, M. W. (2003). Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 61, 39-78.
15. Biron, K. E., Dickstein, D. L., Gopaul, R., and Jefferies, W. A. (2011). Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS ONE 6:e23789. doi: 10.1371/journal.pone.0023789
16. Blann, A. D., Woywodt, A., Bertolini, F., Bull, T. M., Buyon, J. P., Clancy, R. M., et al. (2005). Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. 93, 228-235. doi:10.1267/THRO05020228
17. Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., et al. (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392. doi: 10.1126/science.1123511
18. Bossolasco, P., Cova, L., Calzarossa, C., Servida, F., Mencacci, N. E., Onida, F., et al. (2010). Metalloproteinase alterations in the bone marrow of ALS patients. J. Mol. Med. (Berl.) 88, 553-564. doi: 10.1007/s00109-009-0584-7
19. Bradbury, M. W. (1985). The blood-brain barrier. Transport across the cerebral endothelium. Circ. Res. 57, 213-222. doi: 10.1161/01.RES.57.2.213
20. Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004). Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749. doi: 10.1146/annurev.neuro.27.070203.144244
21. Carman, C. V., and Springer, T. A. (2008). Trans-cellular migration: cell-cell contacts get intimate. Curr. Opin. Cell Biol. 20, 533-540. doi: 10.1016/j.ceb.2008.05.007
22. Chong, A. Y., Lip, G. Y. H., Freestone, B., and Blann, A. D. (2006). Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin. Eur. J. Heart Fail. 8, 167-172. doi: 10.1016/j.ejheart.2005.06.010
23. Claudio, L. (1996). Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. (Berl.) 91, 6-14. doi: 10.1007/s004010050386
24. Cleveland, D. W., and Rothstein, J. D. (2001). From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806-819. doi: 10.1038/35097565
25. Consilvio, C., Vincent, A. M., and Feldman, E. L. (2004). Neuroinflammation, COX-2, and ALS-a dual role? Exp. Neurol. 187, 1-10. doi: 10.1016/j.expneurol.2003.12.009
26. Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Brown, R. H. Jr., Johnson, H., Qureshi, M., et al. (2003). A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61, 456-464. doi: 10.1212/WNL.61.4.456
27. Dalkara, T., Gursoy-Ozdemir, Y., and Yemisci, M. (2011). Brain microvascular pericytes in health and disease. Acta Neuropathol. (Berl.) 122, 1-9. doi: 10.1007/s00401-011-0847-6
28. Dermietzel, R., and Krause, D. (1991). Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry. Int. Rev. Cytol. 127, 57-109.
29. Desai Bradaric, B., Patel, A., Schneider, J. A., Carvey, P. M., and Hendey, B. (2012). Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J. Neural Transm. 119, 59-71. doi: 10.1007/s00702-011-0684-8
30. Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., and Hendey, B. (2009). Evidence of angiogenic vessels in Alzheimer's disease. J. Neural Transm. 116, 587-597. doi: 10.1007/s00702-009-0226-9
31. de Vries, H. E., Kuiper, J., de Boer, A. G., Van Berkel, T. J., and Breimer, D. D. (1997). The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49, 143-155.
32. Donnenfeld, H., Kascsak, R. J., and Bartfeld, H. (1984). Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol. 6, 51-57. doi: 10.1016/0165-5728(84)90042-0
33. Elliott, J. L. (2001). Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 95, 172-178. doi: 10.1016/S0169-328X(01)00242-X
34. Engelhardt, B. (2008). The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr. Pharm. Des. 14, 1555-1565. doi: 10.2174/138161208784705432
35. Engelhardt, J. I., and Appel, S. H. (1990). IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 47, 1210-1216. doi: 10.1001/archneur.1990.00530110068019
36. Engelhardt, J. I., Siklós, L., Kömüves, L., Smith, R. G., and Appel, S. H. (1995). Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 20, 185-199. doi: 10.1002/syn.890200302
37. Engelhardt, J. I., Tajti, J., and Appel, S. H. (1993). Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50, 30-36. doi: 10.1001/archneur.1993.00540010026013
38. Evans, M. C., Couch, Y., Sibson, N., and Turner, M. R. (2013). Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 53, 34-41. doi: 10.1016/j.mcn.2012.10.008
39. Gabathuler, R. (2010). Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48-57. doi: 10.1016/j.nbd.2009.07.028
40. Garbuzova-Davis, S., Haller, E., Saporta, S., Kolomey, I., Nicosia, S. V., and Sanberg, P. R. (2007a). Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 1157, 126-137. doi: 10.1016/j.brainres.2007.04.044
41. Garbuzova-Davis, S., Saporta, S., Haller, E., Kolomey, I., Bennett, S. P., Potter, H., et al. (2007b). Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE 2:e1205. doi: 10.1371/journal.pone.0001205
42. Garbuzova-Davis, S., Hernandez-Ontiveros, D. G., Rodrigues, M. C. O., Haller, E., Frisina-Deyo, A., Mirtyl, S., et al. (2012). Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res. 1469, 114-128. doi: 10.1016/j.brainres.2012.05.056
43. Garbuzova-Davis, S., Rodrigues, M. C. O., Hernandez-Ontiveros, D. G., Louis, M. K., Willing, A. E., Borlongan, C. V., et al. (2011). Amyotrophic lateral sclerosis: a neurovascular disease. Brain Res. 1398, 113-125. doi: 10.1016/j.brainres.2011.04.049
44. Garbuzova-Davis, S., Saporta, S., and Sanberg, P. R. (2008). Implications of blood-brain barrier disruption in ALS. Amyotroph. Lateral Scler. 9, 375-376. doi: 10.1080/17482960802160990
45. Garbuzova-Davis, S., Woods, R. L., Louis, M. K., Zesiewicz, T. A., Kuzmin-Nichols, N., Sullivan, K. L., et al. (2010). Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS ONE 5:e10614. doi: 10.1371/journal.pone.0010614
46. Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., et al. (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045-1053. doi: 10.1016/S1474-4422(07)70270-3
47. Grammas, P., Martinez, J., and Miller, B. (2011). Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 13, e19. doi: 10.1017/S1462399411001918
48. Groeneveld, G. J., Veldink, J. H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., et al. (2003). A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 53, 437-445. doi: 10.1002/ana.10554
49. Haidet-Phillips, A. M., Hester, M. E., Miranda, C. J., Meyer, K., Braun, L., Frakes, A., et al. (2011). Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 29, 824-828. doi: 10.1038/nbt.1957
50. Hall, E. D., Oostveen, J. A., and Gurney, M. E. (1998). Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256. doi: 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#
51. Henkel, J. S., Beers, D. R., Wen, S., Bowser, R., and Appel, S. H. (2009). Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 72, 1614-1616. doi: 10.1212/WNL.0b013e3181a41228
52. Henkel, J. S., Engelhardt, J. I., Siklós, L., Simpson, E. P., Kim, S. H., Pan, T., et al. (2004). Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 55, 221-235. doi: 10.1002/ana.10805
53. Hirschi, K. K., and D'Amore, P. A. (1996). Pericytes in the microvasculature. Cardiovasc. Res. 32, 687-698.
54. Hovden, H., Frederiksen, J. L., and Pedersen, S. W. (2013). Immune system alterations in amyotrophic lateral sclerosis. Acta Neurol. Scand. doi: 10.1111/ane.12125 [Epub ahead of print].
55. Hunting, C. B., Noort, W. A., and Zwaginga, J. J. (2005). Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization. Vox Sang. 88, 1-9. doi: 10.1111/j.1423-0410.2005.00589.x
56. Jablonski, M. R., Jacob, D. A., Campos, C., Miller, D. S., Maragakis, N. J., Pasinelli, P., et al. (2012). Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol. Dis. 47, 194-200. doi: 10.1016/j.nbd.2012.03.040
57. Koh, S.-H., Baik, W., Noh, M. Y., Cho, G. W., Kim, H. Y., Kim, K. S., et al. (2012). The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp. Neurol. 233, 472-480. doi: 10.1016/j.expneurol.2011.11.021
58. Kutcher, M. E., and Herman, I. M. (2009). The pericyte: cellular regulator of microvascular blood flow. Microvasc. Res. 77, 235-246. doi: 10.1016/j.mvr.2009.01.007
59. Leonardi, A., Abbruzzese, G., Arata, L., Cocito, L., and Vische, M. (1984). Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis. J. Neurol. 231, 75-78. doi: 10.1007/BF00313720
60. Ley, K., Laudanna, C., Cybulsky, M. I., and Nourshargh, S. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689. doi: 10.1038/nri2156
61. Liesi, P., and Kauppila, T. (2002). Induction of type IV collagen and other basement-membrane-associated proteins after spinal cord injury of the adult rat may participate in formation of the glial scar. Exp. Neurol. 173, 31-45. doi: 10.1006/exnr.2001.7800
62. Lindsberg, P. J., Strbian, D., and Karjalainen-Lindsberg, M.-L. (2010). Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab. 30, 689-702. doi: 10.1038/jcbfm.2009.282
63. Mantovani, A., Bussolino, F., and Dejana, E. (1992). Cytokine regulation of endothelial cell function. Faseb J. 6, 2591-2599.
64. McCarty, J. H. (2005). Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier. Assay Drug Dev. Technol. 3, 89-95. doi: 10.1089/adt.2005.3.89
65. McGeer, P. L., and McGeer, E. G. (1998). Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12(Suppl. 2), S1-S6. doi: 10.1097/00002093-199803001-00001
66. McGeer, P. L., and McGeer, E. G. (2002). Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26, 459-470. doi: 10.1002/mus.10191
67. Milane, A., Fernandez, C., Dupuis, L., Buyse, M., Loeffler, J.-P., Farinotti, R., et al. (2010). P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci. Lett. 472, 166-170. doi: 10.1016/j.neulet.2010.01.078
68. Misra, A., Ganesh, S., Shahiwala, A., and Shah, S. P. (2003). Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci. 6, 252-273.
69. Mitchell, J. D., and Borasio, G. D. (2007). Amyotrophic lateral sclerosis. Lancet 369, 2031-2041. doi: 10.1016/S0140-6736(07)60944-1
70. Miyazaki, K., Ohta, Y., Nagai, M., Morimoto, N., Kurata, T., Takehisa, Y., et al. (2011). Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J. Neurosci. Res. 89, 718-728. doi: 10.1002/jnr.22594
71. Nadar, S. K., Lip, G. Y. H., Lee, K. W., and Blann, A. D. (2005). Circulating endothelial cells in acute ischaemic stroke. Thromb. Haemost. 94, 707-712.
72. Nag, S. (ed.). (2003). "Morphology and molecular properties of cellular components of normal cerebral vessels, " in The Blood-Brain Barrier: Biology and Research Protocols (Totowa, NJ: Humana Press Inc.), 3-36.
73. Nicaise, C., Mitrecic, D., Demetter, P., De Decker, R., Authelet, M., Boom, A., et al. (2009a). Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 1301, 152-162. doi: 10.1016/j.brainres.2009.09.018
74. Nicaise, C., Soyfoo, M. S., Authelet, M., De Decker, R., Bataveljic, D., Delporte, C., et al. (2009b). Aquaporin-4 overexpression in rat ALS model. Anat. Rec. (Hoboken.) 292, 207-213. doi: 10.1002/ar.20838
75. Nicaise, C., Soyfoo, M. S., Delporte, C., and Pochet, R. (2010). Aquaporin-4 as a potential marker of BBB disruption in ALS models. Amyotroph. Lateral Scler. 11, 253-254. doi: 10.3109/17482960902803457
76. Ono, S., Imai, T., Munakata, S., Takahashi, K., Kanda, F., Hashimoto, K., et al. (1998). Collagen abnormalities in the spinal cord from patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 160, 140-147. doi: 10.1016/S0022-510X(98)00223-8
77. Pardridge, W. M. (1991). Advances in cell biology of blood-brain barrier transport. Semin. Cell Biol. 2, 419-426.
78. Pardridge, W. M. (1999). Blood-brain barrier biology and methodology. J. Neurovirol. 5, 556-569. doi: 10.3109/13550289909021285
79. Pardridge, W. M. (2002). Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug Discov. 1, 131-139. doi: 10.1038/nrd725
80. Pardridge, W. M. (2005). The blood-brain barrier: bottleneck in brain drug development. Neurorx J. Am. Soc. Exp. Neurother. 2, 3-14.
81. Pasinelli, P., and Brown, R. H. (2006). Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7, 710-723. doi: 10.1038/nrn1971
82. Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., and Amin, A. F. (2009). Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 23, 35-58. doi: 10.2165/0023210-200923010-00003
83. Pathan, S. A., Iqbal, Z., Zaidi, S. M. A., Talegaonkar, S., Vohra, D., Jain, G. K., et al. (2009). CNS drug delivery systems: novel approaches. Recent Pat. Drug Deliv. Formul. 3, 71-89. doi: 10.2174/187221109787158355
84. Phatnani, H. P., Guarnieri, P., Friedman, B. A., Carrasco, M. A., Muratet, M., O'Keeffe, S., et al. (2013). Intricate interplay between astrocytes and motor neurons in ALS. Proc. Natl. Acad. Sci. U.S.A. 110, E756-E765. doi: 10.1073/pnas.1222361110
85. Rodrigues, M. C. O., Hernandez-Ontiveros, D. G., Louis, M. K., Willing, A. E., Borlongan, C. V., Sanberg, P. R., et al. (2012). Neurovascular aspects of amyotrophic lateral sclerosis. Int. Rev. Neurobiol. 102, 91-106. doi: 10.1016/B978-0-12-386986-9.00004-1
86. Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62. doi: 10.1038/362059a0
87. Rothstein, J. D. (2009). Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 65(Suppl. 1), S3-S9. doi: 10.1002/ana.21543
88. Rowland, L. P., and Shneider, N. A. (2001). Amyotrophic lateral sclerosis. N. Engl. J. Med. 344, 1688-1700. doi: 10.1056/NEJM200105313442207
89. Rule, R. R., Schuff, N., Miller, R. G., and Weiner, M. W. (2010). Gray matter perfusion correlates with disease severity in ALS. Neurology 74, 821-827. doi: 10.1212/WNL.0b013e3181d3e2dd
90. Sagar, D., Foss, C., El Baz, R., Pomper, M. G., Khan, Z. K., and Jain, P. (2012). Mechanisms of dendritic cell trafficking across the blood-brain barrier. J. Neuroimmune Pharmacol. 7, 74-94. doi: 10.1007/s11481-011-9302-7
91. Saleh, I. A., Zesiewicz, T., Xie, Y., Sullivan, K. L., Miller, A. M., Kuzmin-Nichols, N., et al. (2009). Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J. Neuroimmunol. 215, 96-101. doi: 10.1016/j.jneuroim.2009.07.011
92. Sallusto, F., Impellizzieri, D., Basso, C., Laroni, A., Uccelli, A., Lanzavecchia, A., et al. (2012). T-cell trafficking in the central nervous system. Immunol. Rev. 248, 216-227. doi: 10.1111/j.1600-065X.2012.01140.x
93. Sá-Pereira, I., Brites, D., and Brito, M. A. (2012). Neurovascular unit: a focus on pericytes. Mol. Neurobiol. 45, 327-347. doi: 10.1007/s12035-012-8244-2
94. Schiffer, D., Cordera, S., Cavalla, P., and Migheli, A. (1996). Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139, Suppl. 27-33. doi: 10.1016/0022-510X(96)00073-1
95. Sica, R. E. (2012). Is amyotrophic lateral sclerosis a primary astrocytic disease? Med. Hypotheses 79, 819-822. doi: 10.1016/j.mehy.2012.08.036
96. Simard, J. M., Kent, T. A., Chen, M., Tarasov, K. V., and Gerzanich, V. (2007). Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 6, 258-268. doi: 10.1016/S1474-4422(07)70055-8
97. Sorenson, E. J., Windbank, A. J., Mandrekar, J. N., Bamlet, W. R., Appel, S. H., Armon, C., et al. (2008). Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775. doi: 10.1212/01.wnl.0000335970.78664.36
98. Strong, M. J., Kesavapany, S., and Pant, H. C. (2005). The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol. 64, 649-664. doi: 10.1097/01.jnen.0000173889.71434.ea
99. Van Den Bosch, L., Van Damme, P., Bogaert, E., and Robberecht, W. (2006). The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1068-1082. doi: 10.1016/j.bbadis.2006.05.002
100. Vargas, M. R., and Johnson, J. A. (2010). Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes. Neurother. J. Am. Soc. Exp. Neurother. 7, 471-481. doi: 10.1016/j.nurt.2010.05.012
101. Verstraete, E., Biessels, G.-J., van Den Heuvel, M. P., Visser, F., Luijten, P. R., and van Den Berg, L. H. (2010). No evidence of microbleeds in ALS patients at 7 Tesla MRI. Amyotroph. Lateral Scler. 11, 555-557. doi: 10.3109/17482968.2010.513053
102. Vorbrodt, A. W., and Dobrogowska, D. H. (2003). Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist's view. Brain Res. Brain Res. Rev. 42, 221-242. doi: 10.1016/S0165-0173(03)00177-2
103. Willmore, L. J., and Triggs, W. J. (1984). Effect of phenytoin and corticosteroids on seizures and lipid peroxidation in experimental posttraumatic epilepsy. J. Neurosurg. 60, 467-472. doi: 10.3171/jns.1984.60.3.0467
104. Winkler, E. A., Bell, R. D., and Zlokovic, B. V. (2011). Central nervous system pericytes in health and disease. Nat. Neurosci. 14, 1398-1405. doi: 10.1038/nn.2946
105. Winkler, E. A., Sengillo, J. D., Bell, R. D., Wang, J., and Zlokovic, B. V. (2012). Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J. Cereb. Blood Flow Metab. 32, 1841-1852. doi: 10.1038/jcbfm.2012.113
106. Winkler, E. A., Sengillo, J. D., Sullivan, J. S., Henkel, J. S., Appel, S. H., and Zlokovic, B. V. (2013). Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. (Berl.) 125, 111-120. doi: 10.1007/s00401-012-1039-8
107. Xie, Y., Weydt, P., Howland, D. S., Kliot, M., and Möller, T. (2004). Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport 15, 2513-2516. doi: 10.1097/00001756-200411150-00016
108. Zhong, Z., Deane, R., Ali, Z., Parisi, M., Shapovalov, Y., O'Banion, M. K., et al. (2008). ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 11, 420-422. doi: 10.1038/nn2073